Elipovimab

Elipovimab is a monoclonal antibody designed for the treatment of Ebola virus disease. It is one of the three antibodies in the Ebola treatment drug Inmazeb.

History[edit | edit source]

Elipovimab, along with atoltivimab and maftivimab, was developed by Regeneron Pharmaceuticals as part of a triple-antibody cocktail for the treatment of Ebola virus disease. The drug was approved for use in the United States in October 2020.

Mechanism of action[edit | edit source]

Elipovimab works by binding to the surface glycoprotein of the Ebola virus, preventing the virus from entering human cells. This stops the virus from replicating and spreading throughout the body.

Clinical trials[edit | edit source]

Elipovimab has been tested in several clinical trials, both as a standalone treatment and as part of the Inmazeb cocktail. These trials have shown that the drug is effective in treating Ebola virus disease, with a significant reduction in mortality compared to other treatments.

Side effects[edit | edit source]

Common side effects of elipovimab include fever, chills, fatigue, rash, and nausea. In rare cases, the drug can cause severe allergic reactions.

See also[edit | edit source]

Elipovimab Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.